CVSI earnings analysis
What we found in CVSI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
CV Sciences reported Q2 2026 revenue of $2.985 million, down 17.5% year over year, with gross margin at 48.6% and diluted EPS of $0.00. Operating expenses improved 11.3% to $1.7 million, and new products represented 44% of revenue, but these positives did not offset weaker sales and margin pressure. The filing provides no quantitative guidance, while continued senior secured convertible financing and the absence of formal Item 1A risk-factor disclosures limit visibility into liquidity and forward risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue declined 17.5% year over year
- Q2 revenue was $2.985 million, down 17.5% year over year. Diluted EPS was $0.00, indicating no reported per-share profit improvement despite the company remaining near break-even on an EPS basis.
- Gross margin compressed to 48.6%
- Gross margin was 48.6%, representing a deterioration from the prior-year period according to the supplied earnings analysis. The margin contraction is a negative profitability signal.
- Operating expenses fell to $1.7 million
- Operating expenses decreased 11.3% year over year to $1.7 million, providing cost relief amid lower revenue.
- New products reached 44% of revenue
- New products contributed 44% of Q2 revenue, or approximately $1.31 million based on reported revenue of $2.985 million, supporting product diversification.
- Controls remained effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes during the quarter that materially affected internal control over financial reporting.
- Convertible financing remained active
- The filing includes senior secured convertible notes due July 6, 2027, including notes dated May 31, 2026, June 30, 2026, and July 31, 2026, indicating continued financing activity.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Regulatory pressure and sales decline
- Revenue declined 17.5% year over year to $2.985 million, consistent with ongoing sales pressure. The prior analysis attributed the weakness in part to regulatory pressure, which could continue to constrain demand and distribution.
- Profitability remains pressured
- Gross margin fell to 48.6% while diluted EPS was $0.00. Lower margin conversion could limit the company’s ability to reach sustained profitability even with operating expenses reduced 11.3% to $1.7 million.
- Financing and liquidity risk
- The company has senior secured convertible notes due July 6, 2027, and the 10-Q includes multiple notes dated May 31, June 30, and July 31, 2026. The filing’s Item 1A states that risk factors are “not applicable” because CV Sciences is a smaller reporting company, so no formal risk-factor changes versus the prior filing were disclosed.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.0
- Gross margin
- 48.6%
- Segment
- New products contributed 44% of Q2 revenue, equivalent to approximately $1.31 million based on total revenue of $2.985 million; no formal segment revenue breakdown was provided.
What they said about what is next.
The 10-Q provides no numerical revenue or EPS guidance and does not state that prior guidance was raised, maintained, lowered, or withdrawn. Outlook was not quantified in the supplied filing text.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- CV Sciences reported Q1 2026 results with a revenue decline to $3.2 million, down 11.4% from $3.6 million in Q1 2025, and a gross margin improvement to 48.9%. The company realized an EPS of $0.0 for the quarter, while…
- 10-K · March 26, 2026
- CV Sciences positions itself as a consumer wellness company selling hemp-derived CBD and plant-based food products through four brands (+PlusCBD™, +PlusHLTH™, Cultured Foods™, Lunar Fox™) and manufacturing via Elevated…
- 10-Q · May 14, 2025
- Q1 2025 revenue declined to $3.606M (down $396K or ~9.9% YoY) and gross profit fell to $1.658M (down $195K). Operating results improved to an operating income of $11K (from an operating loss of $620K) largely due to a…
- 10-Q · November 14, 2024
- CV Sciences, Inc. demonstrated a decrease in revenue in Q3 2024, reporting $3,865,000 compared to $4,089,000 in Q3 2023. The net loss widened slightly to $(456,000) from $(447,000) year-over-year, resulting in an EPS of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CVSI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever